Therapeutic use of granulocyte colony-stimulating factor (G-CSF) in patients with febrile neutropenia: a comprehensive systematic review for clinical practice guidelines for the use of G-CSF 2022 from the Japan Society of Clinical Oncology.

Autor: Tsuchihashi K; Department of Hematology, Oncology and Cardiovascular Medicine, Kyushu University Hospital, Fukuoka, Japan., Ito M; Department of Hematology, Oncology and Cardiovascular Medicine, Kyushu University Hospital, Fukuoka, Japan., Okumura Y; Department of Gastrointestinal and Medical Oncology, NHO Kyushu Cancer Center, Fukuoka, Japan., Nio K; Department of Medical Oncology, Hamanomachi Hospital, Fukuoka, Japan., Ozaki Y; Department of Breast Medical Oncology, The Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo, Japan., Nishio H; Department of Obstetrics and Gynecology, Keio University School of Medicine, Tokyo, Japan., Ichihara E; Center for Clinical Oncology, Okayama University Hospital, Okayama, Japan., Miura Y; Department of Medical Oncology, Toranomon Hospital, Tokyo, Japan., Endo M; Department of Orthopaedic Surgery, Kyushu University, Fukuoka, Japan., Yano S; Division of Clinical Oncology/Hematology, Department of Internal Medicine, The Jikei University School of Medicine, Tokyo, Japan., Maruyama D; Department of Hematology Oncology, Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo, Japan., Yoshinami T; Department of Breast and Endocrine Surgery, Graduate School of Medicine, Osaka University, Osaka, Japan., Susumu N; Department of Obstetrics and Gynecology, International University of Health and Welfare Narita Hospital, Chiba, Japan., Takekuma M; Department of Gynecology, Shizuoka Cancer Center, Shizuoka, Japan., Motohashi T; Department of Obstetrics and Gynecology, Tokyo Women's Medical University Hospital, Tokyo, Japan., Ochi N; Department of General Internal Medicine 4, Kawasaki Medical School, Okayama, Japan., Kubo T; Department of Allergy and Respiratory Medicine, Okayama University Hospital, Okayama, Japan., Uchino K; Department of Medical Oncology, NTT Medical Center Tokyo, Tokyo, Japan., Kimura T; Department of Urology, The Jikei University School of Medicine, Tokyo, Japan., Kamiyama Y; Department of Clinical Oncology/Hematology, The Jikei University School of Medicine, Tokyo, Japan., Nakao S; Department of Hematology, Faculty of Medicine, Institute of Medical Pharmaceutical and Health Sciences, Kanazawa University, Ishikawa, Japan., Tamura S; Department of Hematology/Oncology, Wakayama Medical University, Wakayama, Japan., Nishimoto H; Department of Nursing, Okayama University Hospital, Okayama, Japan., Kato Y; Department of Drug Information, Faculty of Pharmaceutical Sciences, Shonan University of Medical Sciences, Kanagawa, Japan., Sato A; Department of Medical Oncology, Hirosaki University Graduate School of Medicine, Aomori, Japan., Takano T; Department of Breast Medical Oncology, The Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo, Japan., Baba E; Department of Oncology and Social Medicine, Graduate School of Medical Sciences, Kyushu University, 3-1-1 Maidashi, Higashi-ku, Fukuoka, 812-8582, Japan. baba.eishi.889@m.kyushu-u.ac.jp.
Jazyk: angličtina
Zdroj: International journal of clinical oncology [Int J Clin Oncol] 2024 Jun; Vol. 29 (6), pp. 700-705. Date of Electronic Publication: 2024 May 02.
DOI: 10.1007/s10147-024-02541-z
Abstrakt: Background: Febrile neutropenia represents a critical oncologic emergency, and its management is pivotal in cancer therapy. In several guidelines, the use of granulocyte colony-stimulating factor (G-CSF) in patients with chemotherapy-induced febrile neutropenia is not routinely recommended except in high-risk cases. The Japan Society of Clinical Oncology has updated its clinical practice guidelines for the use of G-CSF, incorporating a systematic review to address this clinical question.
Methods: The systematic review was conducted by performing a comprehensive literature search across PubMed, the Cochrane Library, and Ichushi-Web, focusing on publications from January 1990 to December 2019. Selected studies included randomized controlled trials (RCTs), non-RCTs, and cohort and case-control studies. Evaluated outcomes included overall survival, infection-related mortality, hospitalization duration, quality of life, and pain.
Results: The initial search yielded 332 records. Following two rounds of screening, two records were selected for both qualitative and quantitative synthesis including meta-analysis. Regarding infection-related mortality, the event to case ratio was 5:134 (3.73%) in the G-CSF group versus 6:129 (4.65%) in the non-G-CSF group, resulting in a relative risk of 0.83 (95% confidence interval, 0.27-2.58; p = 0.54), which was not statistically significant. Only median values for hospitalization duration were available from the two RCTs, precluding a meta-analysis. For overall survival, quality of life, and pain, no suitable studies were found for analysis, rendering their assessment unfeasible.
Conclusion: A weak recommendation is made that G-CSF treatment not be administered to patients with febrile neutropenia during cancer chemotherapy. G-CSF treatment can be considered for patients at high risk.
(© 2024. The Author(s) under exclusive licence to Japan Society of Clinical Oncology.)
Databáze: MEDLINE
Externí odkaz: